UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2019
Commission File Number: 001-38764
Aptorum Group Limited
17th Floor, Guangdong Investment Tower
148 Connaught Road Central
Hong Kong
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
The following exhibits are attached.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: September 9, 2019
| Aptorum Group Limited | ||
| By: | /s/ Sabrina Khan | |
| Sabrina Khan | ||
| Chief Financial Officer | ||
2
EXHIBIT INDEX
3
Exhibit 99.1
NASDAQ: APM
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2019
NEW YORK, September 9, 2019 – Aptorum Group Limited (“Aptorum Group” or the “Company”) (NASDAQ: APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today provided a business update and announced financial results for the six months ended June 30, 2019.
“During the first six months of 2019, Aptorum Group achieved a number of milestones. Across our pipeline, ALS-4, the drug candidate for the treatment of infections caused by Staphylococcus aureus including methicillin-resistant Staphylococcus aureus (MRSA), has been progressing well and already entered IND-enabling studies. The first series of GLP toxicology study has been completed and we plan to target the related IND submission around the first to second calendar quarter of 2020. After which, hybrid clinical studies are being designed and are planned to take place in North America. We are also excited to announce the investigation and development of two new preclinical drug candidates, CLS-1 and SACT-1, targeting obesity and neuroblastoma under our recently announced Claves and Smart-ACTTM platforms respectively. Under both platforms, Aptorum Group will continue to drive the discovery and development of new therapeutic candidates focused on unmet needs related to gastrointestinal microbiome and in the orphan diseases area,” said Ian Huen, Founder and Chief Executive Officer of Aptorum Group. “To promote further exciting venture opportunities, on April 24, 2019, we entered into a Master Collaboration Agreement with Singapore based A*ccelerate Technologies Pte Ltd, the enterprise office of the government research institution Agency for Science, Technology and Research (A*STAR), pursuant to which the parties may contribute up to an aggregate of $90 million cash and in-kind contributions to suitable start-ups. Through this agreement, Aptorum Group and A*ccelerate intend to jointly create a number of deep tech healthcare and life sciences based ventures in Singapore over the next five years.”
Recent Business Updates
| - | Aptorum Group has commenced the investigational new drug (IND)-enabling studies for ALS-4, the small drug molecule candidate indicated for the treatment of infections caused by Staphylococcus aureus including methicillin-resistant Staphylococcus aureus (MRSA, a “super-bug”) based on a novel anti-virulence approach. |
| - | Claves Life Sciences Limited, a wholly owned subsidiary of Aptorum Group, established a novel therapeutic platform for the treatment of various diseases via modulation of the chemical signaling relating to gut microbiota. Investigation and development of a new preclinical drug candidate, CLS-1, targeting obesity have commenced with the view to commence IND enabling studies in 2020. |
| - | Aptorum Group has established a new subsidiary, Smart Pharma, which operates its novel computational repurposed drug discovery, modeling and validation platform, i.e. the Smart-ACTTM platform. Abbreviated for Accelerated Commercialization of Therapeutics, Smart-ACTTM encompasses state-of-the-art technology to perform systematic screening and repurposing of approved drug molecules against thoughtfully selected therapeutic targets. Specifically, the Smart-ACTTM platform comprises of a network of modules and processes that simulate the effectiveness of drug molecules against diseases for outcome prediction and selection. The Smart-ACTTM platform will initially focus on the screening and repurposing of drug molecules for orphan diseases and diseases with other rare unmet medical needs. Under the Smart-ACTTM platform, computational screening has been completed for 1,615 marketed drugs against 3 therapeutic target proteins which are related to poor prognosis of neuroblastoma. The selected candidates under the SACT-1 program, which is looking for a cure for neuroblastoma, are currently being investigated and undergoing preclinical development. |
| - | Aptorum Group, Aeneas Capital Limited and A*ccelerate Technologies Pte Ltd, the enterprise office of the Agency for Science, Technology and Research (A*STAR), signed a contribution agreement to co-create local deep tech start-ups in the healthcare and life sciences sector. Through this agreement, Aptorum Group and A*ccelerate intend to jointly create up to 20 deep tech ventures in Singapore over the next five years. These enterprises will leverage technologies co-developed by A*STAR research institutes and Aptorum Group. The parties agreed to contribute up to an aggregate of $90 million in cash or in-kind contributions to create these ventures. |
1
NASDAQ: APM
Upcoming Milestones
| - | For ALS-4, Aptorum Group anticipates filing an IND submission in the first or second calendar quarter of 2020 and a hybrid Phase 1 clinical study is currently planned in North America with both healthy volunteers and patients to obtain preliminary efficacy readout. |
Financial Results for the Six Months Ended June 30, 2019
Aptorum Group reported a net loss of $9.6 million for the six months ended June 30, 2019 compared to $5.5 million for the same period in 2018. The increase in net loss in current period was driven by increase in research and development expenses, general and administrative fees and legal and professional fees.
Research and development expenses were $2.7 million for the six months ended June 30, 2019 compared to $1.3 million for the same period in 2018. The increase was primarily due to the incurred expenses for new sponsored research entered into with Universities in such period, and the full operation of research and development was started in the second half of 2018 which led to depreciation and increase in payroll expenses since second half of 2018.
General and administrative fees were $3.2 million for the six months ended June 30, 2019 compared to $2.2 million for the same period in 2018. The increase was mainly driven by increased headcount in the Group to support the business development, and the higher amounts of insurance expense incurred after the Company listed its securities on NASDAQ.
Legal and professional fees were $2.0 million for the six months ended June 30, 2019 compared to $1.1 million for the same period in 2018. The increase in legal and professional fees was mainly due to the increasing need for consultancy services on various projects.
As of June 30, 2019, cash and marketable securities totaled approximately $6.1 million and total equity was in excess of $24.0 million.
On August 13, 2019, Aptorum Group entered into financing arrangements allowing the Company to access up to a total $15.0 million in line of credit debt financing. As of the date of this release, the Company has not yet drawn down from this line of credit.
Aptorum Group expects that its existing cash and marketable securities, together with expected and committed cash from existing collaborations, will enable it to fund its operating and capital expenditure requirements to the end of 2020.
2
About Aptorum Group
Aptorum Group is a pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic technologies to tackle unmet medical needs. The company is pursuing therapeutic projects in infectious diseases, gastroenterology, orphan diseases and other disease areas.
For more information about the Company, please visit www.aptorumgroup.com.
Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
3
NASDAQ: APM
APTORUM GROUP LIMITED
CONSOLIDATED BALANCE SHEETS
(Stated in U.S. Dollars)
As of June 30, 2019 | As of December 31, 2018 | |||||||
(unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | 4,466,741 | $ | 12,006,624 | ||||
| Restricted cash | - | 14,100,614 | ||||||
| Digital currencies | 117,482 | - | ||||||
| Accounts receivable | 8,367 | 2,827 | ||||||
| Inventories | 33,911 | 30,642 | ||||||
| Marketable securities, at fair value | 1,669,096 | 1,014,338 | ||||||
| Investments in derivatives | 425,916 | 115,721 | ||||||
| Amounts due from related parties | - | 169,051 | ||||||
| Due from brokers | 109,134 | 818,968 | ||||||
| Other receivables and prepayments | 911,997 | 464,156 | ||||||
| Total current assets | 7,742,644 | 28,722,941 | ||||||
| Property, plant and equipment, net | 5,777,657 | 4,260,602 | ||||||
| Non-marketable investments | 7,112,180 | 7,094,712 | ||||||
| Intangible assets, net | 1,347,594 | 1,409,540 | ||||||
| Amounts due from related parties | 50,000 | 50,000 | ||||||
| Long-term prepayments | 2,048,570 | 3,417,178 | ||||||
| Loan receivable | 571,975 | - | ||||||
| Other non-current asset | 89,750 | 119,667 | ||||||
| Total Assets | $ | 24,740,370 | $ | 45,074,640 | ||||
| LIABILITIES AND EQUITY | ||||||||
| LIABILITIES | ||||||||
| Current liabilities: | ||||||||
| Amounts due to related parties | $ | 3,512 | $ | 33,417 | ||||
| Accounts payable and accrued expenses | 548,433 | 1,247,147 | ||||||
| Finance lease payable, current portion | 45,196 | 43,877 | ||||||
| Warrant liabilities | - | 753,118 | ||||||
| Convertible debts | - | 10,107,306 | ||||||
| Total current liabilities | 597,141 | 12,184,865 | ||||||
| Finance lease payable, non-current portion | 120,941 | 143,873 | ||||||
| Total Liabilities | $ | 718,082 | $ | 12,328,738 | ||||
| Commitments and contingencies | - | - | ||||||
EQUITY | ||||||||
| Class A Ordinary Shares ($1.00 par value; 60,000,000 shares authorized, 6,597,362 shares issued and outstanding as at June 30, 2019 and 6,537,269 shares issued and outstanding as at December 31, 2018, respectively) | $ | 6,597,362 | $ | 6,537,269 | ||||
| Class B Ordinary Shares ($1.00 par value; 40,000,000 shares authorized, 22,437,754 shares issued and outstanding as at June 30, 2019 and December 31, 2018) | 22,437,754 | 22,437,754 | ||||||
| Additional paid-in capital | 23,857,814 | 23,003,285 | ||||||
| Accumulated other comprehensive gain (loss) | 7,345 | (1,484,688 | ) | |||||
| Accumulated deficit | (27,957,689 | ) | (17,379,185 | ) | ||||
| Total equity attributable to the shareholders of Aptorum Group Limited | 24,942,586 | 33,114,435 | ||||||
| Non-controlling interests | (920,298 | ) | (368,533 | ) | ||||
| Total equity | 24,022,288 | 32,745,902 | ||||||
| Total Liabilities and Equity | $ | 24,740,370 | $ | 45,074,640 | ||||
4
NASDAQ: APM
APTORUM GROUP LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Stated in U.S. Dollars)
For the six months ended June 30, | ||||||||
| 2019 | 2018 | |||||||
| (unaudited) | (unaudited) | |||||||
| Revenue | ||||||||
| Healthcare services income | $ | 239,792 | $ | 26,662 | ||||
Operating expenses | ||||||||
| Costs of healthcare services | (371,218 | ) | (22,749 | ) | ||||
| Research and development expenses | (2,714,217 | ) | (1,342,179 | ) | ||||
| General and administrative fees | (3,232,916 | ) | (2,238,025 | ) | ||||
| Legal and professional fees | (2,008,774 | ) | (1,063,032 | ) | ||||
| Other operating expenses | (120,788 | ) | (235,413 | ) | ||||
| Total operating expenses | (8,447,913 | ) | (4,901,398 | ) | ||||
| Other loss | ||||||||
| Gain on investments in marketable securities, net | 315,977 | - | ||||||
| Gain on non-marketable investment | 1,147,199 | - | ||||||
| Gain (loss) on investments in derivatives, net | 310,195 | (359,844 | ) | |||||
| Realized gain on sale of digital currencies | 12,334 | - | ||||||
| Changes in fair value of warrant liabilities | (866,300 | ) | - | |||||
| Gain on extinguishment of convertible debts | 1,198,490 | - | ||||||
| Interest expense, net | (3,678,566 | ) | (301,362 | ) | ||||
| Sundry income | 128,444 | - | ||||||
| Total other loss, net | (1,432,227 | ) | (661,206 | ) | ||||
| Net loss | $ | (9,640,348 | ) | $ | (5,535,942 | ) | ||
| Less: net loss attributable to non-controlling interests | (551,877 | ) | (47,570 | ) | ||||
| Net loss attributable to Aptorum Group Limited | $ | (9,088,471 | ) | $ | (5,488,372 | ) | ||
| Net loss per share – basic and diluted | $ | (0.31 | ) | $ | (0.20 | ) | ||
| Weighted-average shares outstanding – basic and diluted | 28,978,151 | 27,864,135 | ||||||
| Net loss | $ | (9,640,348 | ) | $ | (5,535,942 | ) | ||
Other Comprehensive income (loss) | ||||||||
| Unrealized loss on investments in available-for-sale securities | - | (178,027 | ) | |||||
| Exchange differences on translation of foreign operations | 2,000 | 167 | ||||||
| Other Comprehensive income (loss) | 2,000 | (177,860 | ) | |||||
Comprehensive loss | (9,638,348 | ) | (5,713,802 | ) | ||||
| Less: comprehensive loss attributable to non-controlling interests | (551,877 | ) | (47,570 | ) | ||||
| Comprehensive loss attributable to the shareholders of Aptorum Group Limited | (9,086,471 | ) | (5,666,232 | ) | ||||
5
NASDAQ: APM
Contact
Investor relations:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com
6
Exhibit 99.2
Exhibit 99.3
NASDAQ: APM
Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA
New York, September 9, 2019 – Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces that it has initiated investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule candidate indicated for the treatment of infections caused by Staphylococcus aureus (or “S. aureus”) including methicillin-resistant Staphylococcus aureus (MRSA, i.e., one of the commonly known “super-bugs”) based on a novel anti-virulence approach.
The ALS-4 candidate has been progressing well and the first series of GLP toxicology studies have been completed through an appointed North American based contract research organization (CRO). In particular, ALS-4 candidate did not show any mutagenicity in the in vitro Ames tests. ALS-4 development is on track and the company targets to submit the related IND in the first half year of 2020 and a hybrid Phase 1 clinical study is currently planned in North America with both healthy volunteers and patients to obtain preliminary efficacy readout.
S. aureus is a bacteria which is a leading cause of blood, lung, skin, bone and device-related infections, as well as toxin-related diseases1. It is estimated that patients with S. aureus bacteremia have an average mortality rate of 30%2 and that it is responsible for causing more deaths than AIDS, tuberculosis and viral hepatitis combined3. MRSA and vancomycin-intermediate and resistant S. aureus have also been classified by the World Health Organization (WHO) as high priority pathogens for research and development4.
About ALS-4
ALS-4 is a small molecule drug candidate that is believed to inhibit dehydrosqualene desaturase of S. aureus (incl. MRSA) which is involved in the generation of staphyloxanthin, a commonly visible “golden pigment” covering the bacteria and is primarily responsible for the bacteria’s resistance to attack from reactive oxygen species (ROS) deployed by phagocytic cells and neutrophils5. On this basis, ALS-4 is not bactericidal and through inhibiting the production of staphyloxanthin, S. aureus becomes highly susceptible to the host’s immune clearance. ALS-4 deploys a novel approach towards the treatment of bacterial infection which is significantly different from the bactericidal approach found in most current antibiotics that are experiencing increasing drug resistance issues.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas.
1 Clin Microbiol Rev. 2015 Jul;28(3):603-61.
2 Clin Microbiol Rev. 2012 Apr;25(2):362-86
3 van Hal et al. Clin Microbiol Rev 2012
4 https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
5 mBio 2017 8(5): e01224-17
For more information about Aptorum Group, please visit www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Contact
Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com
Exhibit 99.4
NASDAQ: APM
Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
New York, September 9, 2019 – Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respectively.
About CLS-1: Treatment of obesity via modulation of chemical signaling relating to gut microbiota
Under the recently-announced microbiota modulation platform operated by Aptorum Group’s wholly-owned subsidiary Claves Life Sciences Limited, we have commenced the preclinical development of macromolecule candidate CLS-1 targeting the treatment of obesity. CLS-1 is undergoing lead optimization and is expected to progress into the IND enabling stage in 2020.
The prevalence of obesity continues to escalate globally; however, there is no current optimal therapy for this condition1. For the majority of obese patients, conventional medical therapies (i.e., diet, exercise, behavioral counseling) often have a high failure rate for the long term2. We believe current pharmacotherapy has limited efficacy and is associated with substantial safety issues, and this will provide immeasurable market opportunity for CLS-1.
Chemical signaling of gut microbiota is known to be one of the major causes of obesity1. CLS-1 is an orally administered non-absorbable macromolecule that modulates the metabolite excreted by gut microbiota with high affinity and specificity. In this way, we believe the absorption of this particular metabolite, which is linked to obesity, can be inhibited.
Aptorum Group is also pursuing two further indications based on the modulation of microbiota based chemical signaling involving the above large molecule technology, which we believe to be highly scalable and we hope to be making further announcements regarding our efforts in due course.
1 Protein Cell. May; 9(5): 397–403.
2 Obes Surg. 2012 Jun;22(6):956-66
About SACT-1: Repurposed Drug Candidates for the Treatment of Neuroblastoma
Under the recently announced Smart-ACTTM computational drug discovery platform operated by our wholly-owned subsidiary Smart Pharma Group, Aptorum Group has completed computational screening of approximately 1,615 marketed drugs against 3 therapeutic target proteins to potentially tackle poor prognosis of neuroblastoma, i.e., a rare type of children’s cancer that forms in certain types of nerve tissue and most frequently in the adrenal glands as well as spine, chest, abdomen or neck, especially in children3. For the high-risk group, the 5-year survival rate of this condition is around 40-50% as observed by the American Cancer Society.4 Aptorum Group has identified an array of repurposed candidates and has proceeded to evaluate them in cell-based and animal models in order to validate the candidates’ usage for such new indication and potential efficacies.
Aptorum Group is also pursuing two further indications under the Smart-ACTTM drug discovery platform and hopes to be making further announcements regarding our research in due course.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
About Claves Life Sciences Limited
Claves Life Sciences Limited is a wholly-owned therapeutics subsidiary of Aptorum Group Limited. Claves focuses on the clinical development of therapeutic candidates related to the field of gastroenterology. The potential candidates under review and potentially developed focus on the modulation of gut microbiota-derived metabolites, for the prevention or treatment of diseases. Claves is also exploring a gut microbiota modulation platform that can generate novel customized candidates capable of fine-tuning levels of gut metabolites, potentially treating a wide range of medical conditions.
About Smart Pharma Group
Smart Pharma Group includes Smart Pharmaceutical Limited Partnership, SMTPH Limited and its subsidiaries. The Smart Pharma Group is wholly owned by Aptorum Group Limited. Smart Pharma Group focuses on systematically repurposing existing approved drugs for the treatment of a large array of orphan diseases. Smart Pharma Group conducts both computational based screening and preclinical validations in advancing the development of its repurposed candidates.
For more information about Smart Pharma Group, please visit www.smtph.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Contact
Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Media:
Tel: + 852 2117 6611
Email: info@aptorumgroup.com
3 https://www.cancer.gov/publications/dictionaries/cancer-terms?expand=N
4 See https://www.cancer.org/cancer/neuroblastoma/detection-diagnosis-staging/survival-rates.html.